NovaBay Pharmaceuticals (NBY) Stock Price, News & Analysis

Company Overview

NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through traditional and digital beauty retailers and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.

Key Stats

• Today's Range: $0.68 to $0.75
• 50-Day Range: $0.45 to $0.75
• 52-Week Range: $0.36 to $12.84
• Volume: 106,511 shs
• Average Volume: 1.02 million shs
• Market Capitalization: $3.67 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

NBY Stock Analysis - Frequently Asked Questions

How have NBY shares performed this year?

NovaBay Pharmaceuticals' stock was trading at $7.14 at the start of the year. Since then, NBY shares have decreased by 89.5% and is now trading at $0.75.
View the best growth stocks for 2024 here.

How were NovaBay Pharmaceuticals' earnings last quarter?

NovaBay Pharmaceuticals, Inc. (NYSE:NBY) announced its quarterly earnings data on Tuesday, August, 13th. The company reported ($1.37) EPS for the quarter. The company earned $2.40 million during the quarter. NovaBay Pharmaceuticals had a negative net margin of 91.86% and a negative trailing twelve-month return on equity of 744.33%.

When did NovaBay Pharmaceuticals' stock split?

Shares of NovaBay Pharmaceuticals reverse split before market open on Friday, May 31st 2024. The 1-35 reverse split was announced on Friday, May 31st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 31st 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

How do I buy shares of NovaBay Pharmaceuticals?

Shares of NBY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of NovaBay Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that NovaBay Pharmaceuticals investors own include Adverum Biotechnologies (ADVM), American Resources (AREC), Clearside Biomedical (CLSD), Hello Group (MOMO), Palatin Technologies (PTN), Xeris Biopharma (XERS) and Algonquin Power & Utilities (AQN).

Company Calendar

• Last Earnings: 8/13/2024
• Today: 11/02/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:NBY
• CUSIP: N/A
• CIK: 1389545
• Web: novabay.com
• Phone: 510-899-8800
• Fax: 510-474-1577
• Employees: 30
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($66.0548)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-9,640,000.00
• Net Margins: -91.86%
• Pretax Margin: -93.50%
• Return on Equity: -744.33%
• Return on Assets: -106.89%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.62
• Quick Ratio: 0.43

Sales & Book Value

• Annual Sales: $14.73 million
• Price / Sales: 0.25
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.25 per share
• Price / Book: 0.18

Miscellaneous

• Outstanding Shares: 4,890,000
• Free Float: 4,881,000
• Market Cap: $3.67 million
• Optionable: Not Optionable
• Beta: 0.75